вЂњWe believe that access to accurate and affordable diagnostic services is a necessity across the country. вЂњDoctors and patients rely on diagnostic test results to make informed decisions вЂ“ accurate diagnosis is the first step towards managing diseases and identifying appropriate line of treatment,вЂќ said Ravindra Kumar, Vice President and Head вЂ“ Lupin Diagnostics. The Reference Laboratory in Guwahati has capabilities to conduct a broad spectrum of routine and specialized tests in the fields of molecular diagnostics, cytogenetics, flow cytometry, histopathology, cytology, microbiology, serology, hematology, immunology and routine biochemistry.

The expansion is in line with Lupin DiagnosticsвЂ™ strategy to expand its presence across India and increase access to quality testing. Global pharma major Lupin Limited has announced that Lupin Diagnostics has launched its Reference Laboratory in Guwahati in North East India. What is Dematerialization & It's Process.Difference Between Demat and Trading Account.Documents Required to Open a Demat Account.Aims, Objectives and Importance of Demat Account.Please consult your investment advisor before investing. Capital markets investments are subject to rules and regulations. Financial Express Online does not bear any responsibility for their investment advice. (The stock recommendations in this story are by the respective research analysts and brokerage firms. While those at Motilal Oswal Financial Services are neutral on the stock. Axis Securities has recommended to вЂholdвЂ™ Lupin shares with a target price of Rs 1,100. It has also revised its rating to вЂreduceвЂ™ from вЂaddвЂ™ earlier. Those at HDFC Securities Institutional Equities slashed its target price to Rs 1,040 from Rs 1,220 earlier.

While Rs 960-883 will be excellent support levels,вЂќ AR Ramachandran, Co-founder & Trainer, Tips2Trades, told Financial Express Online.ДЄnalysts at Emkay Global Financial Services have reiterated their вЂbuyвЂ™ rating on the stock but cut target price to Rs1,300 from Rs1,325 as it modestly lower its earnings estimates for FY22/23/24 to reflect the Q1 miss, leading to a lower US revenue base. Long-term investors should start accumulating Lupin at current prices for the near-term targets of Rs 1083-1160. вЂњTechnically, the stock is very oversold. Lupin has seen a sharp correction in its stock price due to competition in famotidine & pending USFDA approvals, said an analyst. Rupee likely to depreciate amid persistent FII outflows, widening trade deficit USDINR to trade in this range Therefore, investors can consider holding the stock with a medium to long term perspective,вЂќ Chepa added. вЂњWe expect its outlook to remain stable on the back of continuous healthy growth in India and gradual ramp-up in US sales which might improve its margins. The operating performance of the firm remained weaker. In traded volume terms, 70,000 shares have traded on BSE, and 15.28 lakh shares exchanged hands on NSE. Since then, this pharma stock has tanked over 24 per cent. Lupin stock surged to a new 52-week high of Rs 1,267.50 apiece in February this year. Check live prices: LupinД«ig Bull Rakesh Jhunjhunwala holds 1.60 per cent stake or 72.45 lakh shares in Lupin as of June quarter. вЂњAlthough the companyвЂ™s Q1 performance was disappointing, its broader narrative on growth remains largely on track,вЂќ Likhita Chepa, Senior Analyst at CapitalVia Global Research told Financial Express Online. Lupin has witnessed a significant amount of correction in the last few trading sessions after the firm failed to meet the earnings expectations of the analysts. Lupin shares have tumbled nearly 17 per cent in seven sessions, falling from Rs 1,150.90 on 6 August 2021. Lupin share price fell nearly 2 per cent to Rs 958.70 apiece in intraday deals, following the April-June quarter earnings last week.

Lupin moneycontrol